Quoin Pharmaceuticals terminates CVRs from prior spin-off; no financial impact

Quoin Pharmaceuticals, Ltd.

CVRs originated from 2021 sale of Cellect Biotherapeutics to EnCellX; Quoin not entitled to proceeds.
Termination certified by EnCellX CEO on Feb 29, 2024; CVRs had no asset or liability recorded.
CVR termination has no financial impact on Quoin; no carrying value on balance sheet.

item 8.01

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-24-031458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.